A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 750 participants.

Also called NCT07214376

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 750 participants (planned count) (from the registry)
Sponsor
Pulnovo Medical, Inc. (from the registry)
Registry
  • NCT NCT07214376
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07214376. Randomized; double masking; primary purpose treatment. Start 2026-08-21 (actual); primary completion 2029-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
Acronym
The PULSE-LHD
Condition
Hypertension
Condition
Vascular Diseases
Condition
Cardiovascular Diseases
Condition
Heart Failure
Condition
Heart Failure With Mid Range Ejection Fraction
Intervention (Device)
Pulmonary Artery Denervation (PADN)
Intervention (Device)
Sham procedure control
Lead sponsor
Pulnovo Medical, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07214376
Content hash
62f99d07fc8e720a280491ecfff3c4386258b9d63aaf0512386c015bd865bad8